10x Genomics, a global leader in single cell and spatial biology, announced it has entered into a definitive agreement to acquire Scale Biosciences, a pioneer in scalable single cell analysis. This acquisition will add key inventions and breakthrough technologies to 10x’s innovation portfolio, enhancing the capabilities of its Chromium platform and making single cell analysis more powerful, affordable, and accessible for researchers worldwide.
Founded by a multidisciplinary team of scientists and technologists, Scale Biosciences brings deep expertise in next-generation sequencing, genomics, and bioinformatics. Its proprietary approaches to combinatorial indexing and quantum barcoding mark a significant advancement in scalable single cell analysis. With this integration, these technologies will now be incorporated into 10x’s global product roadmap, enabling broader adoption and accelerating biological discoveries.
Scale’s scientific founders – Professor Garry Nolan (Stanford University), Professors Jay Shendure and Cole Trapnell (University of Washington), and Frank Steemers — will join 10x as scientific advisors.
“At 10x, we’re relentlessly innovating to build a world where single cell analysis is routine, accessible, and scalable at levels previously unimaginable,” said Serge Saxonov, CEO of 10x Genomics. “This acquisition is a step towards that vision – reflecting our commitment to accelerating adoption of single cell technologies. By integrating Scale’s inventions with 10x’s global platform and innovation engine, we will broaden the capabilities and reach of existing and future products.”
Also Read: Seegene Unveils CURECA™ and STAgora™ at ADLM 2025, Advancing the Next Stage of Diagnostics
By bringing Scale’s technologies into its portfolio, 10x aims to accelerate its multi-year innovation strategy for single cell research. This roadmap focuses on dramatically scaling the number of cells and samples that can be analyzed while preserving the rich, high-quality multiomic data that scientists have come to expect from 10x solutions.
“These inventions were designed to make single cell analysis dramatically more scalable and accessible,” said Garry Nolan, PhD, co-founder of Scale Biosciences and Professor at Stanford University. “They have already advanced biological discovery, and with 10x’s innovation engine, that impact will only accelerate. This integration will help the research community generate the high-quality data needed to drive AI-powered breakthroughs in medicine.”
“We are incredibly proud of what we’ve built at Scale and its impact advancing biological understanding in single cell analysis. Our integration with 10x will accelerate the adoption of our technology, helping it reach new customers and transformative emerging applications,” said Giovanna Prout, President and CEO of Scale Biosciences. “We look forward to 10x building on our pioneering work and supporting a broader global customer base that will drive the next wave of biological discovery.”